Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

被引:284
作者
Coudeville, Laurent [1 ]
Bailleux, Fabrice [1 ]
Riche, Benjamin [2 ]
Megas, Francoise [1 ]
Andre, Philippe [1 ]
Ecochard, Rene [2 ]
机构
[1] Sanofi Pasteur, F-69367 Lyon 07, France
[2] Univ Lyon 1, Lab Biostat Sante, Hosp Civils Lyon, Serv Biostat,CNRS,UMR 5558, F-69365 Lyon, France
来源
BMC MEDICAL RESEARCH METHODOLOGY | 2010年 / 10卷
关键词
SURROGATE END-POINTS; H1N1; VIRUS-VACCINES; INACTIVATED INFLUENZA; TERM IMMUNITY; INFECTION; TRIALS; VACCINATION; EFFICACY; IMMUNOGENICITY; POPULATION;
D O I
10.1186/1471-2288-10-18
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1: 40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. Methods: We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. Results: A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Conclusion: Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
引用
收藏
页数:11
相关论文
共 43 条
  • [1] [Anonymous], 2004, HDB BETA DISTRIBUTIO
  • [2] ARTIFICIALLY INDUCED ASIAN INFLUENZA IN VACCINATED AND UNVACCINATED VOLUNTEERS
    BELL, JA
    WARD, TG
    KAPIKIAN, AZ
    SHELOKOV, A
    REICHELDERFER, TE
    HUEBNER, RJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1957, 165 (11): : 1366 - 1373
  • [3] Seroprotection rate, mean fold increase, seroconversion rate:: which parameter adequately expresses seroresponse to influenza vaccination?
    Beyer, WEP
    Palache, AM
    Lüchters, G
    Nauta, J
    Osterhaus, ADME
    [J]. VIRUS RESEARCH, 2004, 103 (1-2) : 125 - 132
  • [4] Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
    Bresson, Jean-Louis
    Perronne, Christian
    Launay, Odile
    Gerdil, Catherine
    Saville, Melanie
    Wood, John
    Hoeschler, Katja
    Zambon, Maria C.
    [J]. LANCET, 2006, 367 (9523) : 1657 - 1664
  • [5] General methods for monitoring convergence of iterative simulations
    Brooks, SP
    Gelman, A
    [J]. JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS, 1998, 7 (04) : 434 - 455
  • [6] Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49
  • [7] A COMPARISON OF LIVE AND INACTIVATED INFLUENZA A (H1N1) VIRUS-VACCINES .1. SHORT-TERM IMMUNITY
    CLARK, A
    POTTER, CW
    JENNINGS, R
    NICHOLL, JP
    LANGRICK, AF
    SCHILD, GC
    WOOD, JM
    TYRRELL, DAJ
    [J]. JOURNAL OF HYGIENE, 1983, 90 (03) : 351 - 359
  • [8] A COMPARISON OF LIVE AND INACTIVATED INFLUENZA A (H1N1) VIRUS-VACCINES .2. LONG-TERM IMMUNITY
    CLARK, A
    POTTER, CW
    JENNINGS, R
    NICHOLL, JP
    LANGRICK, AF
    SCHILD, GC
    WOOD, JM
    TYRRELL, DAJ
    [J]. JOURNAL OF HYGIENE, 1983, 90 (03) : 361 - 370
  • [9] Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop
    De Gruttola, VG
    Clax, P
    DeMets, DL
    Downing, GJ
    Ellenberg, SS
    Friedman, L
    Gail, MH
    Prentice, R
    Wittes, J
    Zeger, SL
    [J]. CONTROLLED CLINICAL TRIALS, 2001, 22 (05): : 485 - 502
  • [10] de Jong J C, 2003, Dev Biol (Basel), V115, P63